INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by TG Therape...
October 14 2016 - 9:17AM
Business Wire
Levi & Korsinsky, LLP announces that it has commenced an
investigation of TG Therapeutics, Inc. (NASDAQCM:TGTX) concerning
possible violations of federal securities laws by the Company
and/or certain of its officers and directors.
TG Therapeutics, Inc. filed a press release on October 13, 2016
announcing that the Company had filed with the FDA an amended
protocol for its leukemia drug combination, GENUINE Phase 3 Trial.
In the amendments, the Company eliminated part II of the GENUINE
study and reduced the number of randomized patients from 200 to
approximately 120. The Company no longer benefits from of its
previously negotiated Special Protocol Assessment with the FDA.
Following this news, TG Therapeutics, Inc. stock dropped
approximately 17% (-$1.42) to $6.83 per share on intraday
trading.
To obtain additional information about the investigation, go
to:
http://zlk.9nl.com/TG_Therapeutics_TGTX
or contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits.
Attorney advertising. Prior results do not guarantee similar
outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161014005376/en/
Levi & Korsinsky, LLPJoseph E. Levi, Esq.Tel:
212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024